Group items tagged

Celebrate American Independence day with 4th of July with custom made wristbands.

4th International Keloid Symposium is organized by Keloid Research Foundation (KRF) and will be held from Oct 07 - 09, 2022 in Montpellier, Occitanie, France

URF's 4th Global Congress on Psychology and Neuroscience is organized by the United Research Forum and will be held from Apr 18 - 19, 2024 in the UAE. Our Psychology and Psychology and Neuroscience 2024 is prestigious for its idea and forefront content, unmatched networking opportunities, and speaker-benevolent climate.

The meeting will explore innovative solutions such as end-to-end continuous bioprocessing, Single Use Technology, and the Application of AI/ML in bioprocessing.

In "LIVE WORKSHOP ON MIVS ( Minimally Invasive Mitral Valve Surgery) at MIOT International, Chennai held on 4th & 5th April 2014, Dr Gokhale was invited to share his experience in Minimal access heart surgery. He gave a guest lecture on"Lessons learnt with experience in Minimal access heart surgery"

Any prescription for Promethazine hydrochloride 10mg tablets x 56 submitted for payment to the NHSBSA for July 2022 will be reimbursed at the new price of £17.77 not as per the price concession of £13.45 announced in the 4th concessions update published on 29 July 2022, said the Pharmaceutical Services Negotiating Committee (PSNC). In July 2022, PSNC received several reports from contractors unable to obtain Promethazine hydrochloride 10mg tablets (56) at the published Drug Tariff price of £4.24. Therefore, it submitted a request for a price concession, which was granted and subsequently published but this was later withdrawn after confirmation from the Department of Health and Social Care (DHSC) that due to the price change mechanism, the reimbursement price for Promethazine hydrochloride 10mg tablets has increased from £4.24 to £17.77 for July 2022. PSNC said, "Following the price change mechanism rules, for generic drugs (excluding drugs in Category M), a price change up to and including the 8th of the month takes effect for prescriptions dispensed in that same month. Any price change after the 8th takes place in the following month."

Join us for the prestigious Pharmacy Business Awards, the most anticipated event in the pharmacy industry. Celebrating the excellence of community pharmacy, this glittering ceremony is a must-attend for pharmacy professionals. Taking place on October 4th, 2023 in central London, the 23rd edition promises to be a memorable occasion. Esteemed guests include heads of pharmacy organizations, CEOs of renowned manufacturers and wholesalers, esteemed health officials, and even government ministers. It's a gathering of the pharmacy industry's elite, showcasing the outstanding services they provide to the nation. To participate in this prestigious event, simply fill out the official online entry form, selecting up to three award categories from the drop-down boxes. Ensure you submit your entry by July 7th, 2023, as only submitted entries will proceed to the judging stage. Don't miss this opportunity to shine a spotlight on your exceptional contributions to community pharmacy. Save the date: July 7th, 2023, is the deadline for nominations. Secure your place at the Pharmacy Business Awards and be part of an unforgettable evening celebrating the very best in community pharmacy.

The Department of Health and Social Care (DHSC) is encouraging people to come forward for their first and/ or second dose of the Covid vaccine before the free offer ends on Friday (30 June). The NHS's world-leading vaccination programme has so far delivered over 146 million Covid jabs. Building on the success of autumn and spring booster programmes, a seasonal, targeted vaccination offer will remain open for those most at risk, in line with advice from the Joint Committee on Vaccination and Immunisation (JCVI). Health Minister Maria Caulfield said: "As we live with Covid without restrictions on our freedoms, it is right that we move towards a more targeted vaccination offer that prioritises those most at risk, so we can focus our efforts on cutting waiting lists for NHS treatment - one of the Prime Minister's top five priorities. As the offer for any adult to get a Covid vaccine comes to an end on 30 June, I would urge those who have not yet come forward to choose to have the first and second Covid vaccine. It takes minutes to get your jab and thousands of sites are open across England." This year's spring booster programme continues to gather pace, with over two million eligible people receiving their vital top-up dose.

Johnson & Johnson has made it to the list of top 10 most innovative companies in the world released by FOREX.com. The US-based pharmaceutical company is the fourth most innovative company, scoring 8.23/10 in the innovation index. Johnson & Johnson is the only pharmaceutical company making it to top 10 list, which makes it the world's most innovative pharmaceutical company in 2023. The ranking is based on many factors such as the number of US-registered patents in 2022, the number of R&D expenses over the last 12 consecutive months and their last reported intangible assets. The health giant spent £37.16 billion on intangible assets (the second highest after Apple), £11.87 billion on R&D last year and registered 1,377 patents last year.

A fourth dose of Covid-19 vaccine is not needed at present, as latest data shows first booster provides high levels of protection against Omicron variant among older adults, says the Joint Committee on Vaccination and Immunisation (JCVI). After analysing latest data from the UK Health Security Agency (UKHSA), JCVI said: "There is no immediate need to introduce a second booster dose, or fourth jab, to the most vulnerable". Data from UKSHA revealed that single booster dose provides around 90 per cent protection against hospitalisation to those aged 65 and over, even after three months of jab. However, protection against mild symptomatic infection is short-lived and drops to around 30 per cent by about three months. The study, which looked at booster doses in those aged over 65, showed that with two vaccine doses, protection against the infection drops to around 70 per cent after three months and to 50 per cent after six months.

Covid-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months. Executives at the biggest Covid vaccine makers including Pfizer and Moderna said they believe most people who wanted to get vaccinated against Covid have already done so - more than five billion people worldwide. In the coming year, most Covid vaccinations will be booster shots, or first inoculations for children, which are still gaining regulatory approvals around the world, they said. Pfizer, which makes its shot with Germany's BioNTech and Moderna still see a major role for themselves in the vaccine market even as overall demand declines. Upstart US vaccine maker Novavax and Germany's CureVac, which is working with GlaxoSmithKline, are developing vaccines they hope to target at the booster market. The roles of AstraZeneca and Johnson & Johnson, whose shots have been less popular or effective, are expected to decline in this market.

The Joint Committee on Vaccination and Immunisation (JCVI) on Thursday (May 19) said that an anticipated autumn Covid booster campaign would be aimed at people aged over 65, care home residents, frontline health and social care workers and all adults in a clinical risk group. The UK is offering a spring booster to the over-75s, care home residents and immunosuppressed people, and ministers have spoken openly of plans for a further booster campaign in the autumn. In interim advice, the JCVI stopped short of recommending another shot for all adults, though said the advice would be reviewed and updated. "The JCVI's current view is that in autumn 2022, a Covid-19 vaccine should be offered to: residents in a care home for older adults and staff; frontline health and social care workers; all those 65 years of age and over; and adults aged 16 to 64 years who are in a clinical risk group," the UK Health Security Agency said in a statement. Prime minister Boris Johnson, who was fiercely criticised for his handling of the early stages of the pandemic, lifted Covid restrictions in England in February, crediting Britain's quick initial vaccine rollout and the rollout of boosters with breaking the link between cases and deaths.